CeNeRx is a privately held drug development company searching
for new and innovative medicines to help healthcare providers
and patients enhance positive mental health and conquer
neurological diseases.
Based in North Carolina's Research Triangle Park area, CeNeRx
focuses on identifying and developing promising therapeutics to
treat diseases related to neurotransmitters -- therapeutic priorities
include anxiety, bipolar disorder, dementia, depression, epilepsy,
neuropathic pain, schizophrenia, Parkinson's and Alzheimer's
disease.
CeNeRx currently has a series of compounds known as RIMAs
(reversible inhibitors of monoamine oxidase) in phase I
development for the treatment of Major Depressive Disorder.
for new and innovative medicines to help healthcare providers
and patients enhance positive mental health and conquer
neurological diseases.
Based in North Carolina's Research Triangle Park area, CeNeRx
focuses on identifying and developing promising therapeutics to
treat diseases related to neurotransmitters -- therapeutic priorities
include anxiety, bipolar disorder, dementia, depression, epilepsy,
neuropathic pain, schizophrenia, Parkinson's and Alzheimer's
disease.
CeNeRx currently has a series of compounds known as RIMAs
(reversible inhibitors of monoamine oxidase) in phase I
development for the treatment of Major Depressive Disorder.
Welcome to CeNeRx!
what's new with CeNeRx?
| -Former GlaxoSmithKline Neurosciences Head Brings Broad Research & Development Expertise to Help Advance the Company’s CNS Portfolio. read full article here... |
| CeNeRx BioPharma Announces Successful Completion of Phase I Clinical Program for Novel Antidepressant Agent Tyrima™ read full article here... |